ASP Isotopes Nears Helium Production, Advances Stable Isotope Growth

ASP Isotopes is advancing its stable-isotope facilities, with first Silicon-28 and Carbon-14 shipments expected in the second half of the year and Ytterbium-176 production planned later this year. The company is pursuing growth in semiconductor materials, medical isotopes and radiopharmaceuticals, while targeting a Quantum Leap Energy spinoff by year-end and $300 million in EBITDA by 2031. ASP Isotopes NASDAQ: ASPI expects several of its business units to enter commercial production or expand output over the next six months, with Chief Executive Officer Paul Mann highlighting progress in helium, liquefied natural gas, stable isotopes and radiopharmaceuticals during a conference presentation. Mann said the company’s objective is to strengthen access to critical materials used in electronics, nuclear medicine and nuclear energy. Its operations include PET Labs, stable-isotope enrichment facilities in South Africa, the Renergen helium and energy business, and Quantum Leap Energy, which is focused on fuels including high-assay low-enriched uranium and lithium isotopes. Renergen started its Phase 1 plant in South Africa and expects initial product shipments to customers in September. The plant is expected to begin generating free cash flow by year-end. The Phase 1 project is expected to produce approximately 70 million cubic feet per day of helium and 2,500 gigajoules per day of LNG. Mann said that, at assumed prices of $600 per thousand cubic feet for helium and $13 to $14 per gigajoule for LNG, the facility could generate roughly $27 million of revenue and $11 million of gross profit. He added that the company was discussing helium prices in the $800 to $1,000 per thousand cubic feet range, while industry participants had indicated spot prices above $2,000 per thousand cubic feet. Mann said the company expects the Phase 1 facility to reach nameplate capacity by the end of the fourth quarter as additional wells are connected through approximately October. Phase 2 is planned to be substantially larger, with projected capacity of about 900 million cubic feet per day of liquid helium and 34,000 gigajoules per day of LNG. Mann said the project could generate about $370 million of revenue and $300 million of gross profit using assumed prices of $600 per thousand cubic feet for helium and $14 per gigajoule for LNG. He said Phase 2 would be supported by approximately $500 million of debt from the U.S. International Development Finance Corporation and about $250 million from Standard Bank. Construction is expected to take about 44 months, with first production anticipated in 2030 and a first full year of output in 2031. Mann also reiterated the company’s plan, announced in July, to merge the Renergen asset into ENDRA Life Sciences. He said the combined company would be positioned as a NASDAQ-listed helium-focused company. ASP Isotopes has built three stable-isotope facilities in South Africa for Silicon-28, Carbon-14 and Ytterbium-176. Mann said all three were being commissioned or prepared for commercial production. The company has assembled the first 48 enrichment stages and is assembling an additional 48 stages. Mann said the plant is currently enriching Silicon-28 and that first shipments are expected in the second half of the year.